Exploring the prognostic impact of absolute lymphocyte count in patients treated with immune-checkpoint inhibitors
The role of immune checkpoint inhibitors (ICI) expands but affordable and reproducible prognostic biomarkers are needed. We investigated the association between baseline and 3-month absolute lymphocyte count (ALC) and survival for patients on ICI. A retrospective study investigated patients who rece...
Gespeichert in:
| Veröffentlicht in: | BJC reports 2024-04, Vol.2 (1), p.31, Article 31 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 31 |
| container_title | BJC reports |
| container_volume | 2 |
| creator | Conroy, M R O'Sullivan, H Collins, D C Bambury, R M Power, D Grossman, S O'Reilly, S |
| description | The role of immune checkpoint inhibitors (ICI) expands but affordable and reproducible prognostic biomarkers are needed. We investigated the association between baseline and 3-month absolute lymphocyte count (ALC) and survival for patients on ICI.
A retrospective study investigated patients who received ICI July 2014-August 2019. Survival probabilities were calculated for lymphocyte subsets. Univariate and multivariate analyses were performed to investigate risk factors for lymphopenia.
Among 179 patients, median age was 62 and 41% were female. The most common diagnoses were melanoma (41%) and lung cancer (40%). Median PFS was 6.5 months. 27% had baseline lymphopenia (ALC |
| doi_str_mv | 10.1038/s44276-024-00058-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11523911</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3128741716</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1996-e2b9334db3a0056c456c4a32d367e564ade168bd37e05067582171aab72091f83</originalsourceid><addsrcrecordid>eNpVkUFP3DAQhS1UxKKFP8Ch8rGXFNuT2MmpqhC0lVbqpZwtx5nduE3i1HZa9t_jZQHBYTQj-b03Y32EXHH2mTOor2NZCiULJsqCMVbVhTwh50IBLxpQ6sObeUUuY_ydRQBMqUqckRU0FZeKwzkJtw_z4IObdjT1SOfgd5OPyVnqxtnYRP2Wmjb6YUlIh_04997u82j9MiXqJjqb5HBKkaaAJmFH_7vUZ_O4TFjYHu2f2bsnae9al3yIF-R0a4aIl899Te7vbn_dfC82P7_9uPm6KSxvGlmgaBuAsmvB5P9JWx7KgOhAKqxkaTrksm47UMgqJlVVC664Ma0SrOHbGtbkyzF3XtoRO5uvDGbQc3CjCXvtjdPvXybX653_pzmvBDSc54RPzwnB_10wJj26aHEYzIR-iRq4qFWZt8osFUepDT7GgNvXPZzpAzB9BKYzMP0ETB9MH99e-Gp5wQOPR92T8Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3128741716</pqid></control><display><type>article</type><title>Exploring the prognostic impact of absolute lymphocyte count in patients treated with immune-checkpoint inhibitors</title><source>Nature Free</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central</source><source>Springer Nature OA Free Journals</source><creator>Conroy, M R ; O'Sullivan, H ; Collins, D C ; Bambury, R M ; Power, D ; Grossman, S ; O'Reilly, S</creator><creatorcontrib>Conroy, M R ; O'Sullivan, H ; Collins, D C ; Bambury, R M ; Power, D ; Grossman, S ; O'Reilly, S</creatorcontrib><description>The role of immune checkpoint inhibitors (ICI) expands but affordable and reproducible prognostic biomarkers are needed. We investigated the association between baseline and 3-month absolute lymphocyte count (ALC) and survival for patients on ICI.
A retrospective study investigated patients who received ICI July 2014-August 2019. Survival probabilities were calculated for lymphocyte subsets. Univariate and multivariate analyses were performed to investigate risk factors for lymphopenia.
Among 179 patients, median age was 62 and 41% were female. The most common diagnoses were melanoma (41%) and lung cancer (40%). Median PFS was 6.5 months. 27% had baseline lymphopenia (ALC < 1 × 10
cells/L) and no significant difference in PFS or OS to those with normal ALC. However, 31% had lymphopenia at 3 months and significantly shorter OS than those without (9.8 vs 18.3 months, p < 0.001). Those with baseline lymphopenia who recovered counts at 3 months had no difference in PFS (median NR vs 13.0 months, p = 0.48) or OS (22 vs 18.3 months, p = 0.548) to those never lymphopenic. The strongest risk factor for lymphopenia on multivariable analysis was previous radiation therapy (RT).
3-month lymphopenia is a negative prognostic marker in cancer patients on ICI. Previous RT is significantly associated with lymphopenia.</description><identifier>ISSN: 2731-9377</identifier><identifier>EISSN: 2731-9377</identifier><identifier>DOI: 10.1038/s44276-024-00058-6</identifier><identifier>PMID: 39516713</identifier><language>eng</language><publisher>England: Nature Publishing Group UK</publisher><ispartof>BJC reports, 2024-04, Vol.2 (1), p.31, Article 31</ispartof><rights>2024. The Author(s).</rights><rights>The Author(s) 2024 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1996-e2b9334db3a0056c456c4a32d367e564ade168bd37e05067582171aab72091f83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11523911/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11523911/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39516713$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Conroy, M R</creatorcontrib><creatorcontrib>O'Sullivan, H</creatorcontrib><creatorcontrib>Collins, D C</creatorcontrib><creatorcontrib>Bambury, R M</creatorcontrib><creatorcontrib>Power, D</creatorcontrib><creatorcontrib>Grossman, S</creatorcontrib><creatorcontrib>O'Reilly, S</creatorcontrib><title>Exploring the prognostic impact of absolute lymphocyte count in patients treated with immune-checkpoint inhibitors</title><title>BJC reports</title><addtitle>BJC Rep</addtitle><description>The role of immune checkpoint inhibitors (ICI) expands but affordable and reproducible prognostic biomarkers are needed. We investigated the association between baseline and 3-month absolute lymphocyte count (ALC) and survival for patients on ICI.
A retrospective study investigated patients who received ICI July 2014-August 2019. Survival probabilities were calculated for lymphocyte subsets. Univariate and multivariate analyses were performed to investigate risk factors for lymphopenia.
Among 179 patients, median age was 62 and 41% were female. The most common diagnoses were melanoma (41%) and lung cancer (40%). Median PFS was 6.5 months. 27% had baseline lymphopenia (ALC < 1 × 10
cells/L) and no significant difference in PFS or OS to those with normal ALC. However, 31% had lymphopenia at 3 months and significantly shorter OS than those without (9.8 vs 18.3 months, p < 0.001). Those with baseline lymphopenia who recovered counts at 3 months had no difference in PFS (median NR vs 13.0 months, p = 0.48) or OS (22 vs 18.3 months, p = 0.548) to those never lymphopenic. The strongest risk factor for lymphopenia on multivariable analysis was previous radiation therapy (RT).
3-month lymphopenia is a negative prognostic marker in cancer patients on ICI. Previous RT is significantly associated with lymphopenia.</description><issn>2731-9377</issn><issn>2731-9377</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpVkUFP3DAQhS1UxKKFP8Ch8rGXFNuT2MmpqhC0lVbqpZwtx5nduE3i1HZa9t_jZQHBYTQj-b03Y32EXHH2mTOor2NZCiULJsqCMVbVhTwh50IBLxpQ6sObeUUuY_ydRQBMqUqckRU0FZeKwzkJtw_z4IObdjT1SOfgd5OPyVnqxtnYRP2Wmjb6YUlIh_04997u82j9MiXqJjqb5HBKkaaAJmFH_7vUZ_O4TFjYHu2f2bsnae9al3yIF-R0a4aIl899Te7vbn_dfC82P7_9uPm6KSxvGlmgaBuAsmvB5P9JWx7KgOhAKqxkaTrksm47UMgqJlVVC664Ma0SrOHbGtbkyzF3XtoRO5uvDGbQc3CjCXvtjdPvXybX653_pzmvBDSc54RPzwnB_10wJj26aHEYzIR-iRq4qFWZt8osFUepDT7GgNvXPZzpAzB9BKYzMP0ETB9MH99e-Gp5wQOPR92T8Q</recordid><startdate>20240418</startdate><enddate>20240418</enddate><creator>Conroy, M R</creator><creator>O'Sullivan, H</creator><creator>Collins, D C</creator><creator>Bambury, R M</creator><creator>Power, D</creator><creator>Grossman, S</creator><creator>O'Reilly, S</creator><general>Nature Publishing Group UK</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20240418</creationdate><title>Exploring the prognostic impact of absolute lymphocyte count in patients treated with immune-checkpoint inhibitors</title><author>Conroy, M R ; O'Sullivan, H ; Collins, D C ; Bambury, R M ; Power, D ; Grossman, S ; O'Reilly, S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1996-e2b9334db3a0056c456c4a32d367e564ade168bd37e05067582171aab72091f83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Conroy, M R</creatorcontrib><creatorcontrib>O'Sullivan, H</creatorcontrib><creatorcontrib>Collins, D C</creatorcontrib><creatorcontrib>Bambury, R M</creatorcontrib><creatorcontrib>Power, D</creatorcontrib><creatorcontrib>Grossman, S</creatorcontrib><creatorcontrib>O'Reilly, S</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BJC reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Conroy, M R</au><au>O'Sullivan, H</au><au>Collins, D C</au><au>Bambury, R M</au><au>Power, D</au><au>Grossman, S</au><au>O'Reilly, S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Exploring the prognostic impact of absolute lymphocyte count in patients treated with immune-checkpoint inhibitors</atitle><jtitle>BJC reports</jtitle><addtitle>BJC Rep</addtitle><date>2024-04-18</date><risdate>2024</risdate><volume>2</volume><issue>1</issue><spage>31</spage><pages>31-</pages><artnum>31</artnum><issn>2731-9377</issn><eissn>2731-9377</eissn><abstract>The role of immune checkpoint inhibitors (ICI) expands but affordable and reproducible prognostic biomarkers are needed. We investigated the association between baseline and 3-month absolute lymphocyte count (ALC) and survival for patients on ICI.
A retrospective study investigated patients who received ICI July 2014-August 2019. Survival probabilities were calculated for lymphocyte subsets. Univariate and multivariate analyses were performed to investigate risk factors for lymphopenia.
Among 179 patients, median age was 62 and 41% were female. The most common diagnoses were melanoma (41%) and lung cancer (40%). Median PFS was 6.5 months. 27% had baseline lymphopenia (ALC < 1 × 10
cells/L) and no significant difference in PFS or OS to those with normal ALC. However, 31% had lymphopenia at 3 months and significantly shorter OS than those without (9.8 vs 18.3 months, p < 0.001). Those with baseline lymphopenia who recovered counts at 3 months had no difference in PFS (median NR vs 13.0 months, p = 0.48) or OS (22 vs 18.3 months, p = 0.548) to those never lymphopenic. The strongest risk factor for lymphopenia on multivariable analysis was previous radiation therapy (RT).
3-month lymphopenia is a negative prognostic marker in cancer patients on ICI. Previous RT is significantly associated with lymphopenia.</abstract><cop>England</cop><pub>Nature Publishing Group UK</pub><pmid>39516713</pmid><doi>10.1038/s44276-024-00058-6</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2731-9377 |
| ispartof | BJC reports, 2024-04, Vol.2 (1), p.31, Article 31 |
| issn | 2731-9377 2731-9377 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11523911 |
| source | Nature Free; DOAJ Directory of Open Access Journals; PubMed Central; Springer Nature OA Free Journals |
| title | Exploring the prognostic impact of absolute lymphocyte count in patients treated with immune-checkpoint inhibitors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T08%3A45%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Exploring%20the%20prognostic%20impact%20of%20absolute%20lymphocyte%20count%20in%20patients%20treated%20with%20immune-checkpoint%20inhibitors&rft.jtitle=BJC%20reports&rft.au=Conroy,%20M%20R&rft.date=2024-04-18&rft.volume=2&rft.issue=1&rft.spage=31&rft.pages=31-&rft.artnum=31&rft.issn=2731-9377&rft.eissn=2731-9377&rft_id=info:doi/10.1038/s44276-024-00058-6&rft_dat=%3Cproquest_pubme%3E3128741716%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3128741716&rft_id=info:pmid/39516713&rfr_iscdi=true |